脂肪来源干细胞（ADSCs）是目前构建组织工程化软骨较为成熟的种子细胞之一，但是构建软骨移植到皮下环境中容易发生骨化，限制了其临床应用。研究表明，血管化是软骨骨化的前提条件，而血管生长抑制因子（TSP-1）具有强大的抑制血管生成的作用。因此，本研究拟通过TSP-1来抑制血管化从而达到阻止组织工程化软骨骨化的目的。首先，应用基因转染技术过表达ADSCs中的TSP-1基因，增加TSP-1的合成来使皮下环境中构建的软骨维持其去血管化状态；其次，通过不同浓度的TSP-1培养的ADSCs来构建皮下环境中表型稳定的软骨；最后，通过结合含有TSP-1缓释微球的方法使组织工程化软骨在体内环境中达到形态和功能的稳定。本研究期望通过以上三个途径分别从内源性和外源性两个方面探讨利用TSP-1 抑制ADSCs构建组织工程化软骨骨化的具体机制，以及在体内构建表型稳定软骨组织的可行性。

Adipose derived stem cell （ADSCs）is one of the ideal seeding cells in cartilage tissue engineering,however, the tissue engineered cartilage differentiated from ADSCs ossified after subcutaneous implantation, which effects the structure and function of cartilage. Studies indicate Thrombospondin-1 inhibits angiogenesis, and angiogenesis is the basis of ossification. Therefore, we hope to inhibit the angiogenesis and ossification by regulating thrombospondin-1. First, to detect the difference of TSP-1 in the tissue engineered cartilage before and after transplantation, then to study the relationship between TSP-1 and ossification. Then to construct engineered cartilage by overexpression of thrombospondin-1 in ADSCs, and to inhibit theossification. Second, to culture ADSCs in different concentrations of thrombospondin-1, then to construct engineered cartilage. At last, to construct engineered cartilage by seeding ADSCs into the thrombospondin-1 delayed releasing PGA scaffold.So as to maintain the stable phenotype of engineered cartiage after subcutaneous implantation,and provide a theoretical basis for the construct ion of tissue engineering cartilage graft.